{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyPLEjiX6XnWkw7EPHk05kep",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/fangya18/Data-science/blob/master/L.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KMaKJQmNVGcP",
        "outputId": "0ae8387e-cbeb-45eb-f11c-f3a6e35e1e7e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ],
      "source": [
        "\n",
        "# authenticate Bigquery and Google Drive\n",
        "from google.colab import auth\n",
        "auth.authenticate_user()\n",
        "\n",
        "# mount your drive\n",
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "import datetime as dt\n",
        "import re\n",
        "import matplotlib.pyplot as plt\n",
        "from collections import Counter\n",
        "import seaborn as sns\n",
        "from sklearn.linear_model import LinearRegression"
      ],
      "metadata": {
        "id": "kTOee4_lVXHB"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "cd drive/MyDrive/HU/lymphoma/"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Ahg0LrIEVZlt",
        "outputId": "401f7a76-4f39-4c0f-b1d0-b61d550ddcb0"
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/content/drive/MyDrive/HU/lymphoma\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "df = pd.read_csv('LP1.csv')\n",
        "df.head()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 751
        },
        "id": "k5aqcgc_VfZJ",
        "outputId": "24799ff2-9784-4204-8a25-b858ed4bb4f1"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   Rank   NCT Number                                              Title  \\\n",
              "0     1  NCT03415399  Clinical Study of ET190L1 ARTEMIS™ in Relapsed...   \n",
              "1     2  NCT01334502  Everolimus, Rituximab, and Combination Chemoth...   \n",
              "2     3  NCT03039114  Study Evaluating Safety and Efficacy of INCB05...   \n",
              "3     4  NCT04103905  A Study of MIL62 in Treatment of CD20 Positive...   \n",
              "4     5  NCT02741388  A Phase Ib Study of Oral Selinexor in Adult Pa...   \n",
              "\n",
              "   Acronym     Status         Study Results  \\\n",
              "0      NaN  Completed  No Results Available   \n",
              "1      NaN  Completed  No Results Available   \n",
              "2      NaN  Completed  No Results Available   \n",
              "3      NaN  Completed  No Results Available   \n",
              "4  SELINDA  Completed  No Results Available   \n",
              "\n",
              "                                  Conditions  \\\n",
              "0                           Lymphoma, B-Cell   \n",
              "1                                   Lymphoma   \n",
              "2                                   Lymphoma   \n",
              "3  CD20-positive B Cell Non-Hodgkin Lymphoma   \n",
              "4                            B-cell Lymphoma   \n",
              "\n",
              "                                       Interventions  \\\n",
              "0               Biological: ET190L1 ARTEMIS™ T cells   \n",
              "1  Biological: rituximab|Drug: cyclophosphamide|D...   \n",
              "2       Drug: Parsaclisib|Drug: Hexal|Drug: Gazyvaro   \n",
              "3  Drug: Recombinant Humanized Monoclonal Antibod...   \n",
              "4  Drug: selinexor|Drug: Rituximab|Drug: Dexameth...   \n",
              "\n",
              "                                    Outcome Measures  \\\n",
              "0  Maximum Tolerated Dose|Toxicity profile of ET1...   \n",
              "1  MTD of everolimus in combination with R-CHOP|A...   \n",
              "2  Safety and tolerability of parsaclisib in comb...   \n",
              "3  Percentage of Participants Who Experienced a D...   \n",
              "4  Incidence rate of dose-limiting toxicities (DL...   \n",
              "\n",
              "                               Sponsor/Collaborators  ...  \\\n",
              "0         Eureka Therapeutics Inc.|Peking University  ...   \n",
              "1  Alliance for Clinical Trials in Oncology|Natio...  ...   \n",
              "2                                 Incyte Corporation  ...   \n",
              "3                 Beijing Mabworks Biotech Co., Ltd.  ...   \n",
              "4  The Lymphoma Academic Research Organisation|Ka...  ...   \n",
              "\n",
              "                                  Other IDs         Start Date  \\\n",
              "0                           ETCH17CD19AR103  September 9, 2017   \n",
              "1  NCCTG-N1085|CDR0000698584|NCI-2011-02643         March 2012   \n",
              "2  INCB 50465-102 (CITADEL-102)|Parsaclisib  February 15, 2017   \n",
              "3                                MIL62-CT01  February 10, 2017   \n",
              "4                                   SELINDA       October 2016   \n",
              "\n",
              "  Primary Completion Date     Completion Date        First Posted  \\\n",
              "0       December 31, 2020   December 31, 2020    January 30, 2018   \n",
              "1           February 2015         August 2017      April 13, 2011   \n",
              "2          March 30, 2021      March 30, 2021    February 1, 2017   \n",
              "3            May 30, 2019        May 29, 2020  September 26, 2019   \n",
              "4      September 29, 2021  September 29, 2021      April 18, 2016   \n",
              "\n",
              "  Results First Posted Last Update Posted  \\\n",
              "0                  NaN     March 16, 2021   \n",
              "1                  NaN    August 10, 2017   \n",
              "2                  NaN   December 2, 2021   \n",
              "3                  NaN      June 16, 2021   \n",
              "4                  NaN   December 7, 2021   \n",
              "\n",
              "                                           Locations Study Documents  \\\n",
              "0  Peking University Cancer Hospital, Beijing, China             NaN   \n",
              "1  Mayo Clinic Cancer Center, Rochester, Minnesot...             NaN   \n",
              "2  Banner Health, Gilbert, Arizona, United States...             NaN   \n",
              "3  Chinese Academy of Medical Sciences (CAMS) & P...             NaN   \n",
              "4  Institut Jules Bordet, Bruxelles, Belgium|CHU ...             NaN   \n",
              "\n",
              "                                           URL  \n",
              "0  https://ClinicalTrials.gov/show/NCT03415399  \n",
              "1  https://ClinicalTrials.gov/show/NCT01334502  \n",
              "2  https://ClinicalTrials.gov/show/NCT03039114  \n",
              "3  https://ClinicalTrials.gov/show/NCT04103905  \n",
              "4  https://ClinicalTrials.gov/show/NCT02741388  \n",
              "\n",
              "[5 rows x 27 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ea923c8b-553c-41ef-a332-f8489be66fb9\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Rank</th>\n",
              "      <th>NCT Number</th>\n",
              "      <th>Title</th>\n",
              "      <th>Acronym</th>\n",
              "      <th>Status</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Outcome Measures</th>\n",
              "      <th>Sponsor/Collaborators</th>\n",
              "      <th>...</th>\n",
              "      <th>Other IDs</th>\n",
              "      <th>Start Date</th>\n",
              "      <th>Primary Completion Date</th>\n",
              "      <th>Completion Date</th>\n",
              "      <th>First Posted</th>\n",
              "      <th>Results First Posted</th>\n",
              "      <th>Last Update Posted</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Study Documents</th>\n",
              "      <th>URL</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>NCT03415399</td>\n",
              "      <td>Clinical Study of ET190L1 ARTEMIS™ in Relapsed...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Completed</td>\n",
              "      <td>No Results Available</td>\n",
              "      <td>Lymphoma, B-Cell</td>\n",
              "      <td>Biological: ET190L1 ARTEMIS™ T cells</td>\n",
              "      <td>Maximum Tolerated Dose|Toxicity profile of ET1...</td>\n",
              "      <td>Eureka Therapeutics Inc.|Peking University</td>\n",
              "      <td>...</td>\n",
              "      <td>ETCH17CD19AR103</td>\n",
              "      <td>September 9, 2017</td>\n",
              "      <td>December 31, 2020</td>\n",
              "      <td>December 31, 2020</td>\n",
              "      <td>January 30, 2018</td>\n",
              "      <td>NaN</td>\n",
              "      <td>March 16, 2021</td>\n",
              "      <td>Peking University Cancer Hospital, Beijing, China</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://ClinicalTrials.gov/show/NCT03415399</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2</td>\n",
              "      <td>NCT01334502</td>\n",
              "      <td>Everolimus, Rituximab, and Combination Chemoth...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Completed</td>\n",
              "      <td>No Results Available</td>\n",
              "      <td>Lymphoma</td>\n",
              "      <td>Biological: rituximab|Drug: cyclophosphamide|D...</td>\n",
              "      <td>MTD of everolimus in combination with R-CHOP|A...</td>\n",
              "      <td>Alliance for Clinical Trials in Oncology|Natio...</td>\n",
              "      <td>...</td>\n",
              "      <td>NCCTG-N1085|CDR0000698584|NCI-2011-02643</td>\n",
              "      <td>March 2012</td>\n",
              "      <td>February 2015</td>\n",
              "      <td>August 2017</td>\n",
              "      <td>April 13, 2011</td>\n",
              "      <td>NaN</td>\n",
              "      <td>August 10, 2017</td>\n",
              "      <td>Mayo Clinic Cancer Center, Rochester, Minnesot...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://ClinicalTrials.gov/show/NCT01334502</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>3</td>\n",
              "      <td>NCT03039114</td>\n",
              "      <td>Study Evaluating Safety and Efficacy of INCB05...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Completed</td>\n",
              "      <td>No Results Available</td>\n",
              "      <td>Lymphoma</td>\n",
              "      <td>Drug: Parsaclisib|Drug: Hexal|Drug: Gazyvaro</td>\n",
              "      <td>Safety and tolerability of parsaclisib in comb...</td>\n",
              "      <td>Incyte Corporation</td>\n",
              "      <td>...</td>\n",
              "      <td>INCB 50465-102 (CITADEL-102)|Parsaclisib</td>\n",
              "      <td>February 15, 2017</td>\n",
              "      <td>March 30, 2021</td>\n",
              "      <td>March 30, 2021</td>\n",
              "      <td>February 1, 2017</td>\n",
              "      <td>NaN</td>\n",
              "      <td>December 2, 2021</td>\n",
              "      <td>Banner Health, Gilbert, Arizona, United States...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://ClinicalTrials.gov/show/NCT03039114</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>4</td>\n",
              "      <td>NCT04103905</td>\n",
              "      <td>A Study of MIL62 in Treatment of CD20 Positive...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Completed</td>\n",
              "      <td>No Results Available</td>\n",
              "      <td>CD20-positive B Cell Non-Hodgkin Lymphoma</td>\n",
              "      <td>Drug: Recombinant Humanized Monoclonal Antibod...</td>\n",
              "      <td>Percentage of Participants Who Experienced a D...</td>\n",
              "      <td>Beijing Mabworks Biotech Co., Ltd.</td>\n",
              "      <td>...</td>\n",
              "      <td>MIL62-CT01</td>\n",
              "      <td>February 10, 2017</td>\n",
              "      <td>May 30, 2019</td>\n",
              "      <td>May 29, 2020</td>\n",
              "      <td>September 26, 2019</td>\n",
              "      <td>NaN</td>\n",
              "      <td>June 16, 2021</td>\n",
              "      <td>Chinese Academy of Medical Sciences (CAMS) &amp; P...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://ClinicalTrials.gov/show/NCT04103905</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>5</td>\n",
              "      <td>NCT02741388</td>\n",
              "      <td>A Phase Ib Study of Oral Selinexor in Adult Pa...</td>\n",
              "      <td>SELINDA</td>\n",
              "      <td>Completed</td>\n",
              "      <td>No Results Available</td>\n",
              "      <td>B-cell Lymphoma</td>\n",
              "      <td>Drug: selinexor|Drug: Rituximab|Drug: Dexameth...</td>\n",
              "      <td>Incidence rate of dose-limiting toxicities (DL...</td>\n",
              "      <td>The Lymphoma Academic Research Organisation|Ka...</td>\n",
              "      <td>...</td>\n",
              "      <td>SELINDA</td>\n",
              "      <td>October 2016</td>\n",
              "      <td>September 29, 2021</td>\n",
              "      <td>September 29, 2021</td>\n",
              "      <td>April 18, 2016</td>\n",
              "      <td>NaN</td>\n",
              "      <td>December 7, 2021</td>\n",
              "      <td>Institut Jules Bordet, Bruxelles, Belgium|CHU ...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://ClinicalTrials.gov/show/NCT02741388</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5 rows × 27 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ea923c8b-553c-41ef-a332-f8489be66fb9')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-ea923c8b-553c-41ef-a332-f8489be66fb9 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-ea923c8b-553c-41ef-a332-f8489be66fb9');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df.columns = df.columns.str.lower()"
      ],
      "metadata": {
        "id": "mnioilnvVowJ"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df[['start date','completion date']] = df[['start date','completion date']].apply(pd.to_datetime)\n",
        "df['duration'] = (df['completion date'] - df['start date']).dt.days"
      ],
      "metadata": {
        "id": "UEdPMXICWItT"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Q1oXSSrkWUJ0",
        "outputId": "2872c50f-78bc-41b4-b064-b37b32d97154"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['rank', 'nct number', 'title', 'acronym', 'status', 'study results',\n",
              "       'conditions', 'interventions', 'outcome measures',\n",
              "       'sponsor/collaborators', 'gender', 'age', 'phases', 'enrollment',\n",
              "       'funded bys', 'study type', 'study designs', 'other ids', 'start date',\n",
              "       'primary completion date', 'completion date', 'first posted',\n",
              "       'results first posted', 'last update posted', 'locations',\n",
              "       'study documents', 'url'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import warnings\n",
        "warnings.filterwarnings(\"ignore\")\n",
        "df1= df[['title','interventions','duration','gender','age','enrollment','sponsor/collaborators']]\n",
        "df1['sponsor/collaborators']=df['sponsor/collaborators'].str.lower()\n",
        "df1['age']=df['age'].str.lower()\n",
        "df1['title']=df['title'].str.lower()\n",
        "df1['interventions']=df['interventions'].str.lower()\n",
        "df1['locations']=df['locations'].str.lower()\n",
        "df1.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 337
        },
        "id": "cbLSaDoiWWiy",
        "outputId": "0ae0ae14-06b8-4afb-b3a7-9af6087f9737"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                               title  \\\n",
              "0  clinical study of et190l1 artemis™ in relapsed...   \n",
              "1  everolimus, rituximab, and combination chemoth...   \n",
              "2  study evaluating safety and efficacy of incb05...   \n",
              "3  a study of mil62 in treatment of cd20 positive...   \n",
              "4  a phase ib study of oral selinexor in adult pa...   \n",
              "\n",
              "                                       interventions  duration gender  \\\n",
              "0               biological: et190l1 artemis™ t cells    1209.0    All   \n",
              "1  biological: rituximab|drug: cyclophosphamide|d...    1979.0    All   \n",
              "2       drug: parsaclisib|drug: hexal|drug: gazyvaro    1504.0    All   \n",
              "3  drug: recombinant humanized monoclonal antibod...    1204.0    All   \n",
              "4  drug: selinexor|drug: rituximab|drug: dexameth...    1824.0    All   \n",
              "\n",
              "                                           age  enrollment  \\\n",
              "0    18 years and older   (adult, older adult)         4.0   \n",
              "1    18 years and older   (adult, older adult)        26.0   \n",
              "2    18 years and older   (adult, older adult)        26.0   \n",
              "3    18 years and older   (adult, older adult)        27.0   \n",
              "4  18 years to 70 years   (adult, older adult)        39.0   \n",
              "\n",
              "                               sponsor/collaborators  \\\n",
              "0         eureka therapeutics inc.|peking university   \n",
              "1  alliance for clinical trials in oncology|natio...   \n",
              "2                                 incyte corporation   \n",
              "3                 beijing mabworks biotech co., ltd.   \n",
              "4  the lymphoma academic research organisation|ka...   \n",
              "\n",
              "                                           locations  \n",
              "0  peking university cancer hospital, beijing, china  \n",
              "1  mayo clinic cancer center, rochester, minnesot...  \n",
              "2  banner health, gilbert, arizona, united states...  \n",
              "3  chinese academy of medical sciences (cams) & p...  \n",
              "4  institut jules bordet, bruxelles, belgium|chu ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-6412274d-4dbb-415d-9218-b6a2c89b4141\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>interventions</th>\n",
              "      <th>duration</th>\n",
              "      <th>gender</th>\n",
              "      <th>age</th>\n",
              "      <th>enrollment</th>\n",
              "      <th>sponsor/collaborators</th>\n",
              "      <th>locations</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>clinical study of et190l1 artemis™ in relapsed...</td>\n",
              "      <td>biological: et190l1 artemis™ t cells</td>\n",
              "      <td>1209.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>4.0</td>\n",
              "      <td>eureka therapeutics inc.|peking university</td>\n",
              "      <td>peking university cancer hospital, beijing, china</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>everolimus, rituximab, and combination chemoth...</td>\n",
              "      <td>biological: rituximab|drug: cyclophosphamide|d...</td>\n",
              "      <td>1979.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>26.0</td>\n",
              "      <td>alliance for clinical trials in oncology|natio...</td>\n",
              "      <td>mayo clinic cancer center, rochester, minnesot...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>study evaluating safety and efficacy of incb05...</td>\n",
              "      <td>drug: parsaclisib|drug: hexal|drug: gazyvaro</td>\n",
              "      <td>1504.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>26.0</td>\n",
              "      <td>incyte corporation</td>\n",
              "      <td>banner health, gilbert, arizona, united states...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>a study of mil62 in treatment of cd20 positive...</td>\n",
              "      <td>drug: recombinant humanized monoclonal antibod...</td>\n",
              "      <td>1204.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>27.0</td>\n",
              "      <td>beijing mabworks biotech co., ltd.</td>\n",
              "      <td>chinese academy of medical sciences (cams) &amp; p...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>a phase ib study of oral selinexor in adult pa...</td>\n",
              "      <td>drug: selinexor|drug: rituximab|drug: dexameth...</td>\n",
              "      <td>1824.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years to 70 years   (adult, older adult)</td>\n",
              "      <td>39.0</td>\n",
              "      <td>the lymphoma academic research organisation|ka...</td>\n",
              "      <td>institut jules bordet, bruxelles, belgium|chu ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-6412274d-4dbb-415d-9218-b6a2c89b4141')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-6412274d-4dbb-415d-9218-b6a2c89b4141 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-6412274d-4dbb-415d-9218-b6a2c89b4141');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Cut Level for duration\n",
        "dcat=pd.cut(df1.duration, bins=[0,366,732,1100,3000],\n",
        "             labels=[\"a1year\", \"a2year\" ,\"a3year\", \"m3year\"])\n",
        "df1.insert(5, \"Dcat\", dcat)\n"
      ],
      "metadata": {
        "id": "vk9F5_VAWhOm"
      },
      "execution_count": 13,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df1['ecat']= np.where(df1['enrollment']<50, 'Less50','Greater50')"
      ],
      "metadata": {
        "id": "0VJ0uyKma37Y"
      },
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df1.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 424
        },
        "id": "BtCp6JC3Wref",
        "outputId": "1bdcb153-b866-4865-f14d-1cb47fda0bef"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                               title  \\\n",
              "0  clinical study of et190l1 artemis™ in relapsed...   \n",
              "1  everolimus, rituximab, and combination chemoth...   \n",
              "2  study evaluating safety and efficacy of incb05...   \n",
              "3  a study of mil62 in treatment of cd20 positive...   \n",
              "4  a phase ib study of oral selinexor in adult pa...   \n",
              "\n",
              "                                       interventions  duration gender  \\\n",
              "0               biological: et190l1 artemis™ t cells    1209.0    All   \n",
              "1  biological: rituximab|drug: cyclophosphamide|d...    1979.0    All   \n",
              "2       drug: parsaclisib|drug: hexal|drug: gazyvaro    1504.0    All   \n",
              "3  drug: recombinant humanized monoclonal antibod...    1204.0    All   \n",
              "4  drug: selinexor|drug: rituximab|drug: dexameth...    1824.0    All   \n",
              "\n",
              "                                           age    Dcat  enrollment  \\\n",
              "0    18 years and older   (adult, older adult)  m3year         4.0   \n",
              "1    18 years and older   (adult, older adult)  m3year        26.0   \n",
              "2    18 years and older   (adult, older adult)  m3year        26.0   \n",
              "3    18 years and older   (adult, older adult)  m3year        27.0   \n",
              "4  18 years to 70 years   (adult, older adult)  m3year        39.0   \n",
              "\n",
              "                               sponsor/collaborators  \\\n",
              "0         eureka therapeutics inc.|peking university   \n",
              "1  alliance for clinical trials in oncology|natio...   \n",
              "2                                 incyte corporation   \n",
              "3                 beijing mabworks biotech co., ltd.   \n",
              "4  the lymphoma academic research organisation|ka...   \n",
              "\n",
              "                                           locations    ecat  \n",
              "0  peking university cancer hospital, beijing, china  Less50  \n",
              "1  mayo clinic cancer center, rochester, minnesot...  Less50  \n",
              "2  banner health, gilbert, arizona, united states...  Less50  \n",
              "3  chinese academy of medical sciences (cams) & p...  Less50  \n",
              "4  institut jules bordet, bruxelles, belgium|chu ...  Less50  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-506a8ce3-46e4-40bb-82c3-f766d346ec90\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>interventions</th>\n",
              "      <th>duration</th>\n",
              "      <th>gender</th>\n",
              "      <th>age</th>\n",
              "      <th>Dcat</th>\n",
              "      <th>enrollment</th>\n",
              "      <th>sponsor/collaborators</th>\n",
              "      <th>locations</th>\n",
              "      <th>ecat</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>clinical study of et190l1 artemis™ in relapsed...</td>\n",
              "      <td>biological: et190l1 artemis™ t cells</td>\n",
              "      <td>1209.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>4.0</td>\n",
              "      <td>eureka therapeutics inc.|peking university</td>\n",
              "      <td>peking university cancer hospital, beijing, china</td>\n",
              "      <td>Less50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>everolimus, rituximab, and combination chemoth...</td>\n",
              "      <td>biological: rituximab|drug: cyclophosphamide|d...</td>\n",
              "      <td>1979.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>alliance for clinical trials in oncology|natio...</td>\n",
              "      <td>mayo clinic cancer center, rochester, minnesot...</td>\n",
              "      <td>Less50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>study evaluating safety and efficacy of incb05...</td>\n",
              "      <td>drug: parsaclisib|drug: hexal|drug: gazyvaro</td>\n",
              "      <td>1504.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>incyte corporation</td>\n",
              "      <td>banner health, gilbert, arizona, united states...</td>\n",
              "      <td>Less50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>a study of mil62 in treatment of cd20 positive...</td>\n",
              "      <td>drug: recombinant humanized monoclonal antibod...</td>\n",
              "      <td>1204.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>27.0</td>\n",
              "      <td>beijing mabworks biotech co., ltd.</td>\n",
              "      <td>chinese academy of medical sciences (cams) &amp; p...</td>\n",
              "      <td>Less50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>a phase ib study of oral selinexor in adult pa...</td>\n",
              "      <td>drug: selinexor|drug: rituximab|drug: dexameth...</td>\n",
              "      <td>1824.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years to 70 years   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>39.0</td>\n",
              "      <td>the lymphoma academic research organisation|ka...</td>\n",
              "      <td>institut jules bordet, bruxelles, belgium|chu ...</td>\n",
              "      <td>Less50</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-506a8ce3-46e4-40bb-82c3-f766d346ec90')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-506a8ce3-46e4-40bb-82c3-f766d346ec90 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-506a8ce3-46e4-40bb-82c3-f766d346ec90');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Enrollement vs Duration\n",
        "1. patients =<50\n",
        "2. patients >50\n",
        "\n",
        "* It makes a difference"
      ],
      "metadata": {
        "id": "LHAkbO2wXEPD"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "def fplot(var,label):\n",
        "    fig, ax=plt.subplots(1,4)\n",
        "    sns.violinplot(x=var, y=\"duration\",data=df1,palette=\"Set2\",ax=ax[0])\n",
        "    sns.histplot(df1,x=\"duration\", hue=var, palette=\"Set2\",kde=True,ax=ax[1])\n",
        "    sns.countplot(x=var,hue=\"Dcat\",data=df1,palette=\"Set2\", ax=ax[2])\n",
        "    sns.barplot(x=var , y=\"duration\",palette=\"Set2\", data=df1,ax=ax[3])\n",
        "    plt.suptitle(label)\n",
        "    return plt\n",
        "fig.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "njRKY1p_XBW7",
        "outputId": "4f66ecb0-81f4-409a-90c6-f2fab2b1b76d"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 0 Axes>"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df1.groupby('ecat')['duration'].agg(['count','mean'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 143
        },
        "id": "NkwM2S7MBwom",
        "outputId": "bdb39c2b-fb5b-47c1-f7fe-4b21e05bc81f"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "           count         mean\n",
              "ecat                         \n",
              "Greater50    373  2133.075067\n",
              "Less50       716  1608.786313"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-b2448c1b-5e44-4e5b-bdcb-dba0eb227dde\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "      <th>mean</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ecat</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>Greater50</th>\n",
              "      <td>373</td>\n",
              "      <td>2133.075067</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Less50</th>\n",
              "      <td>716</td>\n",
              "      <td>1608.786313</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-b2448c1b-5e44-4e5b-bdcb-dba0eb227dde')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-b2448c1b-5e44-4e5b-bdcb-dba0eb227dde button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-b2448c1b-5e44-4e5b-bdcb-dba0eb227dde');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fplot(\"ecat\",\"enrollment\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 515
        },
        "id": "cLyWLP-DbhDG",
        "outputId": "ed31e8b8-4152-414b-8cbc-c83f4b054587"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<module 'matplotlib.pyplot' from '/usr/local/lib/python3.10/dist-packages/matplotlib/pyplot.py'>"
            ]
          },
          "metadata": {},
          "execution_count": 18
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 4 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"ecat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "rjk2XCvtY74x",
        "outputId": "d58598d9-4017-47d1-81b2-df399d472fd1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import scipy.stats as stats"
      ],
      "metadata": {
        "id": "_hLwd-MLb1KL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Sponsor vs Duration\n",
        "1. Industrial or Academic\n",
        "\n",
        "Note: We only count industry solo, collaboration is counted in acdemics"
      ],
      "metadata": {
        "id": "K4ESYz-te-QV"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "values=[\"university\", \"academic\", \"research\" ,\"hospital\", \"organization\"]"
      ],
      "metadata": {
        "id": "VFxke6Hff6Bf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Industry vs Academic\n",
        "df1[\"indcat\"]=np.where(df1[\"sponsor/collaborators\"].str.contains('|'.join(values)),\"CorA\" ,\"IndSolo\")\n",
        "dfa= df1[df1.indcat.isin([\"N\"])]\n",
        "dfb=df1[df1.indcat.isin([\"Y\"])]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vrwNr60weF80",
        "outputId": "b1945010-375c-401b-eccd-8305c9568215"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-15-4ae14a001bcb>:2: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df1[\"indcat\"]=np.where(df1[\"sponsor/collaborators\"].str.contains('|'.join(values)),\"CorA\" ,\"IndSolo\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df1.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 337
        },
        "id": "IProTq_ggJY1",
        "outputId": "910f3bb9-a1b3-4d1d-e362-9259471f63ac"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                               title  \\\n",
              "0  clinical study of et190l1 artemis™ in relapsed...   \n",
              "1  everolimus, rituximab, and combination chemoth...   \n",
              "2  study evaluating safety and efficacy of incb05...   \n",
              "3  a study of mil62 in treatment of cd20 positive...   \n",
              "4  a phase ib study of oral selinexor in adult pa...   \n",
              "\n",
              "                                       interventions  duration gender  \\\n",
              "0               biological: et190l1 artemis™ t cells    1209.0    All   \n",
              "1  biological: rituximab|drug: cyclophosphamide|d...    1979.0    All   \n",
              "2       drug: parsaclisib|drug: hexal|drug: gazyvaro    1504.0    All   \n",
              "3  drug: recombinant humanized monoclonal antibod...    1204.0    All   \n",
              "4  drug: selinexor|drug: rituximab|drug: dexameth...    1824.0    All   \n",
              "\n",
              "                                           age    Dcat  enrollment  \\\n",
              "0    18 years and older   (adult, older adult)  m3year         4.0   \n",
              "1    18 years and older   (adult, older adult)  m3year        26.0   \n",
              "2    18 years and older   (adult, older adult)  m3year        26.0   \n",
              "3    18 years and older   (adult, older adult)  m3year        27.0   \n",
              "4  18 years to 70 years   (adult, older adult)  m3year        39.0   \n",
              "\n",
              "                               sponsor/collaborators    ecat   indcat  \n",
              "0         eureka therapeutics inc.|peking university  Less50     CorA  \n",
              "1  alliance for clinical trials in oncology|natio...  Less50  IndSolo  \n",
              "2                                 incyte corporation  Less50  IndSolo  \n",
              "3                 beijing mabworks biotech co., ltd.  Less50  IndSolo  \n",
              "4  the lymphoma academic research organisation|ka...  Less50     CorA  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-e7b611fa-9a46-46f4-9161-d1f4b917c7cb\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>interventions</th>\n",
              "      <th>duration</th>\n",
              "      <th>gender</th>\n",
              "      <th>age</th>\n",
              "      <th>Dcat</th>\n",
              "      <th>enrollment</th>\n",
              "      <th>sponsor/collaborators</th>\n",
              "      <th>ecat</th>\n",
              "      <th>indcat</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>clinical study of et190l1 artemis™ in relapsed...</td>\n",
              "      <td>biological: et190l1 artemis™ t cells</td>\n",
              "      <td>1209.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>4.0</td>\n",
              "      <td>eureka therapeutics inc.|peking university</td>\n",
              "      <td>Less50</td>\n",
              "      <td>CorA</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>everolimus, rituximab, and combination chemoth...</td>\n",
              "      <td>biological: rituximab|drug: cyclophosphamide|d...</td>\n",
              "      <td>1979.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>alliance for clinical trials in oncology|natio...</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>study evaluating safety and efficacy of incb05...</td>\n",
              "      <td>drug: parsaclisib|drug: hexal|drug: gazyvaro</td>\n",
              "      <td>1504.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>incyte corporation</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>a study of mil62 in treatment of cd20 positive...</td>\n",
              "      <td>drug: recombinant humanized monoclonal antibod...</td>\n",
              "      <td>1204.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>27.0</td>\n",
              "      <td>beijing mabworks biotech co., ltd.</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>a phase ib study of oral selinexor in adult pa...</td>\n",
              "      <td>drug: selinexor|drug: rituximab|drug: dexameth...</td>\n",
              "      <td>1824.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years to 70 years   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>39.0</td>\n",
              "      <td>the lymphoma academic research organisation|ka...</td>\n",
              "      <td>Less50</td>\n",
              "      <td>CorA</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-e7b611fa-9a46-46f4-9161-d1f4b917c7cb')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-e7b611fa-9a46-46f4-9161-d1f4b917c7cb button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-e7b611fa-9a46-46f4-9161-d1f4b917c7cb');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fplot(\"indcat\",\"Industry\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 515
        },
        "id": "o0LbQNiggN0A",
        "outputId": "c9400622-18d5-4cb3-b768-5d64dd6f8f8b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<module 'matplotlib.pyplot' from '/usr/local/lib/python3.10/dist-packages/matplotlib/pyplot.py'>"
            ]
          },
          "metadata": {},
          "execution_count": 17
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 4 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"indcat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "UcG8rpblhII_",
        "outputId": "7dfd12e7-6fff-4698-8734-0750c5f08784"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Age\n",
        "1. Any study contains Adult or children\n",
        "2. Child solo"
      ],
      "metadata": {
        "id": "0F028t8fht5w"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Adult vs Child Solo\n",
        "pd.set_option(\"max_colwidth\", 200)\n",
        "df1[\"acat\"]=np.where(df1[\"age\"].str.contains(\"adult\"),\"CAdult\" ,\"ChildSolo\")\n",
        "df1.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 583
        },
        "id": "GiPvPfa5hte2",
        "outputId": "ac31ca38-393a-4824-d7a6-55af64c0528e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-52-0d867f14f181>:3: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df1[\"acat\"]=np.where(df1[\"age\"].str.contains(\"adult\"),\"CAdult\" ,\"ChildSolo\")\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                        title  \\\n",
              "0                                                                                  clinical study of et190l1 artemis™ in relapsed, refractory b cell lymphoma   \n",
              "1                       everolimus, rituximab, and combination chemotherapy in treating patients with newly diagnosed untreated diffuse large b-cell lymphoma   \n",
              "2  study evaluating safety and efficacy of incb050465 combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (citadel-102)   \n",
              "3                                                                                             a study of mil62 in treatment of cd20 positive b-cell lymphomas   \n",
              "4                                    a phase ib study of oral selinexor in adult patients with relapsed/refractory b-cell lymphoma receiving r-dhaox or r-gdp   \n",
              "\n",
              "                                                                                                                              interventions  \\\n",
              "0                                                                                                      biological: et190l1 artemis™ t cells   \n",
              "1  biological: rituximab|drug: cyclophosphamide|drug: doxorubicin hydrochloride|drug: everolimus|drug: prednisone|drug: vincristine sulfate   \n",
              "2                                                                                              drug: parsaclisib|drug: hexal|drug: gazyvaro   \n",
              "3                                                                           drug: recombinant humanized monoclonal antibody mil62 injection   \n",
              "4                  drug: selinexor|drug: rituximab|drug: dexamethasone|drug: oxaliplatin|drug: cisplatin|drug: cytarabine|drug: gemcitabine   \n",
              "\n",
              "   duration gender                                          age    Dcat  \\\n",
              "0    1209.0    All    18 years and older   (adult, older adult)  m3year   \n",
              "1    1979.0    All    18 years and older   (adult, older adult)  m3year   \n",
              "2    1504.0    All    18 years and older   (adult, older adult)  m3year   \n",
              "3    1204.0    All    18 years and older   (adult, older adult)  m3year   \n",
              "4    1824.0    All  18 years to 70 years   (adult, older adult)  m3year   \n",
              "\n",
              "   enrollment  \\\n",
              "0         4.0   \n",
              "1        26.0   \n",
              "2        26.0   \n",
              "3        27.0   \n",
              "4        39.0   \n",
              "\n",
              "                                                      sponsor/collaborators  \\\n",
              "0                                eureka therapeutics inc.|peking university   \n",
              "1  alliance for clinical trials in oncology|national cancer institute (nci)   \n",
              "2                                                        incyte corporation   \n",
              "3                                        beijing mabworks biotech co., ltd.   \n",
              "4   the lymphoma academic research organisation|karyopharm therapeutics inc   \n",
              "\n",
              "     ecat   indcat    acat  \n",
              "0  Less50     CorA  CAdult  \n",
              "1  Less50  IndSolo  CAdult  \n",
              "2  Less50  IndSolo  CAdult  \n",
              "3  Less50  IndSolo  CAdult  \n",
              "4  Less50     CorA  CAdult  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-690b1aed-ac5f-4c7c-a563-3daffaa70ec2\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>interventions</th>\n",
              "      <th>duration</th>\n",
              "      <th>gender</th>\n",
              "      <th>age</th>\n",
              "      <th>Dcat</th>\n",
              "      <th>enrollment</th>\n",
              "      <th>sponsor/collaborators</th>\n",
              "      <th>ecat</th>\n",
              "      <th>indcat</th>\n",
              "      <th>acat</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>clinical study of et190l1 artemis™ in relapsed, refractory b cell lymphoma</td>\n",
              "      <td>biological: et190l1 artemis™ t cells</td>\n",
              "      <td>1209.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>4.0</td>\n",
              "      <td>eureka therapeutics inc.|peking university</td>\n",
              "      <td>Less50</td>\n",
              "      <td>CorA</td>\n",
              "      <td>CAdult</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>everolimus, rituximab, and combination chemotherapy in treating patients with newly diagnosed untreated diffuse large b-cell lymphoma</td>\n",
              "      <td>biological: rituximab|drug: cyclophosphamide|drug: doxorubicin hydrochloride|drug: everolimus|drug: prednisone|drug: vincristine sulfate</td>\n",
              "      <td>1979.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>alliance for clinical trials in oncology|national cancer institute (nci)</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "      <td>CAdult</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>study evaluating safety and efficacy of incb050465 combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (citadel-102)</td>\n",
              "      <td>drug: parsaclisib|drug: hexal|drug: gazyvaro</td>\n",
              "      <td>1504.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>26.0</td>\n",
              "      <td>incyte corporation</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "      <td>CAdult</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>a study of mil62 in treatment of cd20 positive b-cell lymphomas</td>\n",
              "      <td>drug: recombinant humanized monoclonal antibody mil62 injection</td>\n",
              "      <td>1204.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years and older   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>27.0</td>\n",
              "      <td>beijing mabworks biotech co., ltd.</td>\n",
              "      <td>Less50</td>\n",
              "      <td>IndSolo</td>\n",
              "      <td>CAdult</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>a phase ib study of oral selinexor in adult patients with relapsed/refractory b-cell lymphoma receiving r-dhaox or r-gdp</td>\n",
              "      <td>drug: selinexor|drug: rituximab|drug: dexamethasone|drug: oxaliplatin|drug: cisplatin|drug: cytarabine|drug: gemcitabine</td>\n",
              "      <td>1824.0</td>\n",
              "      <td>All</td>\n",
              "      <td>18 years to 70 years   (adult, older adult)</td>\n",
              "      <td>m3year</td>\n",
              "      <td>39.0</td>\n",
              "      <td>the lymphoma academic research organisation|karyopharm therapeutics inc</td>\n",
              "      <td>Less50</td>\n",
              "      <td>CorA</td>\n",
              "      <td>CAdult</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-690b1aed-ac5f-4c7c-a563-3daffaa70ec2')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-690b1aed-ac5f-4c7c-a563-3daffaa70ec2 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-690b1aed-ac5f-4c7c-a563-3daffaa70ec2');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 52
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"acat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "k6hGUNTti-d4",
        "outputId": "fdff0a38-ddd7-4a0c-ec2b-2dd2b379f276"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Title\n",
        "1. Contain refractory or relapse\n",
        "2. Contain navie"
      ],
      "metadata": {
        "id": "zZ2rSxCpmFeP"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# reftractory or relapsed\n",
        "pattern = re.compile(r\"\\b(refractory|relapse|replapsed)|relapsed/refractory|efficacy|transplantation|transplant|combination|immuno\\b\", re.IGNORECASE)\n",
        "df1[\"ccat\"]=np.where(df1[\"title\"].str.contains(pattern),\"RR\" ,\"naive\")"
      ],
      "metadata": {
        "id": "AC9Af-IYmPyV"
      },
      "execution_count": 40,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df1.groupby('ccat')['duration'].agg(['count','mean'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 143
        },
        "id": "e5WURTlMC970",
        "outputId": "a8f01ab2-4dd9-49c7-f212-8140cdbdaf01"
      },
      "execution_count": 41,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       count         mean\n",
              "ccat                     \n",
              "RR       544  1922.121324\n",
              "naive    545  1654.851376"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-81811baa-1c0d-431d-b88b-85e1a2dfdc37\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "      <th>mean</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ccat</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>RR</th>\n",
              "      <td>544</td>\n",
              "      <td>1922.121324</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>naive</th>\n",
              "      <td>545</td>\n",
              "      <td>1654.851376</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-81811baa-1c0d-431d-b88b-85e1a2dfdc37')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-81811baa-1c0d-431d-b88b-85e1a2dfdc37 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-81811baa-1c0d-431d-b88b-85e1a2dfdc37');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 41
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"ccat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "NbholbkJnAGB",
        "outputId": "cc075cb5-f0e5-439d-ef83-a1dd63af2ca9"
      },
      "execution_count": 42,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# immuno\n",
        "pattern = re.compile(r\"\\b(immuno)\\b\", re.IGNORECASE)\n",
        "df1[\"ccat\"]=np.where(df1[\"title\"].str.contains(pattern),\"immuno\" ,\"other\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Eh_X8IzQnJpq",
        "outputId": "30f25110-d5a4-46e4-fbc6-659110257e23"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-55-aadf85eef87e>:3: UserWarning: This pattern is interpreted as a regular expression, and has match groups. To actually get the groups, use str.extract.\n",
            "  df1[\"ccat\"]=np.where(df1[\"title\"].str.contains(pattern),\"immuno\" ,\"other\")\n",
            "<ipython-input-55-aadf85eef87e>:3: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df1[\"ccat\"]=np.where(df1[\"title\"].str.contains(pattern),\"immuno\" ,\"other\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"ccat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "XdGTHUMenQ75",
        "outputId": "a8bd2557-897a-41a9-9c2b-d5b45a49c0ff"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Intervention\n",
        "1. Rituximab\n",
        "2. Other"
      ],
      "metadata": {
        "id": "ZXTCapzBne5J"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# rituximab\n",
        "pattern = re.compile(r\"\\b(rituximab)\\b\", re.IGNORECASE)\n",
        "df1[\"icat\"]=np.where(df1[\"interventions\"].str.contains(pattern),\"ritu\" ,\"other\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "_BbwQOPqnWPM",
        "outputId": "51cb50f3-c010-42d7-f030-0008c61d16a7"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-58-74df9e2e2109>:3: UserWarning: This pattern is interpreted as a regular expression, and has match groups. To actually get the groups, use str.extract.\n",
            "  df1[\"icat\"]=np.where(df1[\"interventions\"].str.contains(pattern),\"ritu\" ,\"other\")\n",
            "<ipython-input-58-74df9e2e2109>:3: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  df1[\"icat\"]=np.where(df1[\"interventions\"].str.contains(pattern),\"ritu\" ,\"other\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"icat\" , y=\"duration\",palette=\"Set2\", data=df1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "Lh3yuBown5ZS",
        "outputId": "bbcf7fa6-fdb2-40c6-b059-8eef2569abbe"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install openai"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RKE9jQiEfiT5",
        "outputId": "09806688-8247-472f-89eb-dfe6bcf807cc"
      },
      "execution_count": 44,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting openai\n",
            "  Downloading openai-0.27.8-py3-none-any.whl (73 kB)\n",
            "\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/73.6 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m73.6/73.6 kB\u001b[0m \u001b[31m2.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: requests>=2.20 in /usr/local/lib/python3.10/dist-packages (from openai) (2.27.1)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from openai) (4.65.0)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from openai) (3.8.4)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (1.26.16)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2023.5.7)\n",
            "Requirement already satisfied: charset-normalizer~=2.0.0 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2.0.12)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.4)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (23.1.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (6.0.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0.0a3 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (4.0.2)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.9.2)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.1)\n",
            "Installing collected packages: openai\n",
            "Successfully installed openai-0.27.8\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "import uuid\n",
        "import time\n",
        "import os\n",
        "import openai\n",
        "openai.api_key = \"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\"\n",
        "model_list = openai.Model.list()"
      ],
      "metadata": {
        "id": "E7m6Ycdyfd-l"
      },
      "execution_count": 57,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.set_option(\"max_colwidth\", 500)\n",
        "dff1= df[['outcome measures','duration']]\n",
        "dff1.columns = dff1.columns.str.replace(\" \",\"_\")\n",
        "dff1['outcome_measures']=dff1['outcome_measures'].str.lower()"
      ],
      "metadata": {
        "id": "05BXpbKofnOK"
      },
      "execution_count": 46,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# EFF vs non safety\n",
        "pattern = re.compile(r\"\\b(overall survival|os|pfs|progression free survival|best overall survival|bor|duration of response|cr|crr|complete response)\\b\", re.IGNORECASE)\n",
        "dff1[\"target\"]=np.where(dff1[\"outcome_measures\"].str.contains(pattern),1,0)\n"
      ],
      "metadata": {
        "id": "U7ySTIFuj3iC"
      },
      "execution_count": 63,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "dff1.groupby('target')['duration'].agg(['count','mean'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 143
        },
        "id": "A_o4kVnpMOY-",
        "outputId": "9db2b9f5-1788-4e5d-995b-fde131c8f706"
      },
      "execution_count": 64,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "        count         mean\n",
              "target                    \n",
              "0         635  1671.056693\n",
              "1         454  1952.438326"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-5d58465f-62fc-44a8-ad71-ae2ea42f2881\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "      <th>mean</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>target</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>635</td>\n",
              "      <td>1671.056693</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>454</td>\n",
              "      <td>1952.438326</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5d58465f-62fc-44a8-ad71-ae2ea42f2881')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-5d58465f-62fc-44a8-ad71-ae2ea42f2881 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-5d58465f-62fc-44a8-ad71-ae2ea42f2881');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 64
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "group_size = 60\n",
        "#train_df = pd.concat([df[df.target==1].sample(group_size), df[df.target==0].sample(group_size)]).reset_index(drop=True)\n",
        "train_df=dff1[:900]\n",
        "train_df.sample(50)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "YzsrNh11H5rQ",
        "outputId": "c4bc160b-e8e4-4153-9cf3-8547c8c7a68d"
      },
      "execution_count": 53,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        outcome_measures  \\\n",
              "741  relationship between the pharmacokinetics and measures of renal dysfunction categorized by creatinine clearance as estimated by the cockcroft and gault formula (part 1)|severity of hepatic disease as assessed by the child-pugh criteria|distribution of and association patterns between the child-pugh score and that of patient's risk of toxicity beyond each dose or cohort, assessed using the national cancer institute common terminology criteria for adverse events (nci ctcae) v3.0|mean levels of...   \n",
              "323  number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events|number of subjects experiencing dose-limiting toxicities|number of subjects who develop anti-drug antibodies (ada)|time to response|duration of response|progression free survival|time to progression|event free survival|overall survival|medi4736 maximum plasma concentration (cmax)|tremelimumab maximum plasma concentration (cmax)|azd9150 maximum plasma concentration (cmax)|medi4736 ...   \n",
              "243                                       maximum tolerated dose/maximum administered dose (mtd/mad) (phase 1)|complete response rate (crr); percentage of participants experiencing positron emission tomography (pet)-negative complete response (cr) (phase 2)|overall response rate (orr); percentage of participants who achieve a pr or cr according to the lugano criteria.|orr by predictive gene signature|progression-free survival (pfs)|event-free survival (efs)|overall survival (os)|adverse events (aes)   \n",
              "768                                                                                                  change in the absolute number of cmv-induced adaptive nk cells (cd56dimcd57+nkg2c+) between days 28 and 100 post-auto-hct in patients with lymphoid malignancies.|change in absolute number of cmv-induced adaptive nk cells|response to cmv-mva triplex vaccine in cmv seropositive vs. seronegative patients|progression free survival (pfs)|response to cmv-mva triplex vaccine in lymphoma vs. myeloma patients   \n",
              "654  safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ecg, and incidence and severity of adverse events|area under the plasma concentration vs. time curve (auc) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|peak plasma concentration (cmax) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|trough plasma concentration (...   \n",
              "316                                                                                                                                                                                                                                                                                                                                                                                                                               maximum tolerated dose of lapatinib and everolimus (part i)|pharmacokinetics (part ii)   \n",
              "692  number of participants with dose limiting toxicities (dlts)|overall response rate (orr) based on investigator assessment|overall response rate based on blinded independent review committee (birc) assessment|duration of response (dor) based on investigator assessment|duration of response (dor) based on birc|progression-free survival based on investigator assessment|progression-free survival based on birc assessment|primary pharmacokinetics (pk) parameter: auc0-last|primary pharmacokinetics (p...   \n",
              "259                                                                                                                                                                                                                                                                                                                                                                                                                                                number of patients with adverse events|plasma concentration over time   \n",
              "642                                                                                                                                                                                                                                                                                                    identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in cll/sll|define dose limiting toxicities of bendamustine, rituximab and lenalidomide in cll|clinical efficacy   \n",
              "625                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NaN   \n",
              "277                                                                                                                                                   the dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.|the response rate after treatment.|responsiveness of patient lymphoblasts to mtor inhibition using in-vitro and in-vivo pharmacodynamic (pd) assessments.|minimal residual disease (mrd) levels present at end of cycle 1 therapy in patients with bone marrow involvement.   \n",
              "775                                                                                                                                                                                                                                                                                                                                                                                                                                                        overall response|maximum tolerated dose (mtd) of mitoxantrone   \n",
              "309                                                                                                                                                                                                                                                                                                                                                                                                                                                   maximum tolerated dose|recommended phase ii dose|toxicity|efficacy   \n",
              "30                                                                  safety as assessed by dose limiting toxicities (dlts)|safety as assessed by determination of the maximum tolerated dose (mtd)|safety as assessed by determination of the recommended phase 2 dose (rp2d)|safety as assessed by and adverse events, laboratory assessments and physical examinations|safety as assessed by mini-mental state examination (mmse)|overall response rate|duration of response|progression free survival|overall survival   \n",
              "110                                                                                                                                                                                                                                                                                    phase i part: determination of the recommended dose of rad001 in combination with rituximab.|phase ii part: complete response rate (cr+cru)|overall response rate|progression-free survival|overall survival|duration of response   \n",
              "524  maximum tolerated dose (mtd) of iv amd3100 + g-csf in mobilization of peripheral blood stem cell in patients with lymphoma (phase i only)|number of participants who experienced dose limiting toxicities in phase i portion of study|kinetics of stem cell mobilization using iv amd3100 as measured by median fold change in the number of cd34+ cells after amd3100 iv administration|pharmacodynamic response to a dose of sc amd3100 as measured by mean percentage of the circulating cd34+ count with the...   \n",
              "667                                                                                                                                                                                                                                                                                                                                            complete remission rate|incidence of adverse events (aes)|incidence of dose-limiting toxicities|overall best response rate|duration of response|progression-free survival   \n",
              "736                                                                                                                                                                                                                                                                                                                                                        rates and routes of excretion of lbh589 and its metabolites in urine and feces following administration of a single oral dose of [14c] lbh589|safety efficacy   \n",
              "643                                                                                                                                                                                                                                                                                                                                                    objective response rate|assessment of the number of events and number and percentage of patients with treatment-emergent aes|time to progression|overall survival   \n",
              "492                                                                                                                                                                                                                                                                                                                                                                                                                                     phase i-ii study of dose dense of peg-filgrastim and gm-csf combined with chop-r   \n",
              "361                                                                                                                                                                                                 overall response rate (orr) of nivolumab in combination with bendamustine hydrochloride in patients with hodgkin's lymphoma|frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03|duration of response (dor)|time to progression (ttp)|progression-free survival (pfs)|overall survival (os)   \n",
              "172                                                                                                                                                                                                                                                                                                                                                                                    maximum tolerated dose of 4-hpr/lxs oral powder|safety|toxicity|level of fenretinide in normal peripheral blood mononuclear cells   \n",
              "114                                              maximum tolerated dose (mtd) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (dlt) graded using the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 (phase i)|progression free survival (pfs) of the combination of lenalidomide, with or without idelalisib (phase ii)|overall survival (os) (phase ii)|overall response rate (partial or complete response) (phase ii)   \n",
              "449  phase 1b: recommended phase 2 dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in participants with relapsed or refractory diffuse large b cell lymphoma (dlbcl)|phase 1b: number of participants with treatment-emergent adverse events (teaes), serious teaes, and discontinuations due to teaes|phase 2: overall response rate (orr)|phase 1b: orr|phase 1b: complete response (cr) rate|phase 2: cr rate|phase 2: duration of response (dor)|phase 2: progression free surviv...   \n",
              "479  percentage of participants with a best overall response (or) of complete response (cr) or partial response (pr) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c)|duration of objective response (dor) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c)|percentage of participants with cr at end of treatment (eot) based on positron emission tomographic...   \n",
              "885  number of participants dlt in arm 1 in dose escalation phase|number of participants dlt in arm 2 in dose escalation phase|response as per investigator assessment for patients with acute myelogenous leukemia (aml)|response as per investigator assessment for patients with acute myelogenous leukemia (aml) in expansion phase|response as per investigator assessment for patients with hodgkin's lymphoma (hd)|response as per investigator assessment for patients with myelodysplastic syndromes (mds)|m...   \n",
              "47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NaN   \n",
              "130                                                                                                                                                                                                              maximum tolerated dose (mtd) and dose limiting toxicity (dlt)|recommended phase 2 dose|pharmacokinetics (pk) in humans of intravenously administered cx-3543.|evaluate evidence of antitumor activity of cx-3543 by objective radiographic assessment.|pharmacodynamic evaluation of antitumor activity   \n",
              "777                                                                                                                                                                                                                                    clinical response (complete or partial remission)|number of participants with dose-limiting toxicities|test the safety and tolerability of the combination of everolimus and alemtuzumab.|survival time|progression-free survival|duration of response|time to subsequent therapy   \n",
              "159                                                                                                                                                                                                                                                                                                                                                                                      maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|number of patients with adverse events   \n",
              "601                                                                                                                                                                                                                                                                                                                                                             tolerance and safety as measured by any ≥ grade iv granulocyte toxicity or any grade iii toxicity thought to be drug related at 1 week after each course   \n",
              "663                                                                                                                                                                                                                                           maximum tolerated dose (mtd) and/or a recommended phase ii dose (phase i)|complete response (cr) defined as the proportion of subjects who achieve cr (phase ii)|objective response rate (orr) (phase ii)|event free survival (efs) (phase ii)|incidence of adverse events   \n",
              "770                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NaN   \n",
              "731                                                                                                                                                                                                                                                                                                                                                                                                                                             maximum tolerated dose acceptable for participants|overall response rate   \n",
              "714                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NaN   \n",
              "23                                                                                                                                                                                                                                                                                                                                                                      safety: incidence and severity of (serious) adverse events n each patient according to the nci-ctcae4.03 grading|concentration of drug in plasma   \n",
              "695                                                                                                                                                                                                                                                                              maximum tolerated dose of vorinostat|safety and toxicity according to ctcae v3.0|efficacy (response rate) of vorinostat combined with rice chemotherapy|ability to proceed to peripheral blood stem cell collection following treatment   \n",
              "260                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NaN   \n",
              "374                                                                                                                                                                                                                                                                                                                                                                                                                                                   mtd of lenalidomide (phase i) progression free survival (phase ii)   \n",
              "177                                                                                                                                                                                                                                                                                                                                                                                                           best objective response based on recist criteria (evaluable for response analysis set for recist criteria)   \n",
              "879                                                                                                                                 number of infusion reaction|number of graft failure|time to neutrophil engraftment|time to platelets engraftment|number of transplant-related mortality (trm)|number of disease free survivals|number of overall survivals|number of participants at risk of gvhd|number of infectious complications|time to myeloid engraftment|time to lymphoid engraftment|change in t cell count   \n",
              "333  number of subjects with adverse events as a measure of safety and tolerability|disease assessments in bone marrow & by computed tomography (ct)/ magnetic resonance imaging (mri)|pharmacokinetics of bms-906024 and its metabolite bms-911557: maximum observed concentration (cmax)|pharmacokinetics of bms-906024 and its metabolite bms-911557: minimum observed concentration (cmin)|pharmacokinetics of bms-906024 and its metabolite bms-911557: area under the concentration-time curve (auc)|pharmacoki...   \n",
              "129                                                                                                                              maximum tolerated dose (mtd)|response will be evaluated every 2 cycles (8 weeks), according to the revised recist guideline, version 1.1|maximum plasma concentration (cmax) of apg-115 on day 1-3 and day 21-23 post apg-115 treatment on cycle 1|area under the plasma concentration versus time curve (auc) of apg-115 on day 1 -3 and day 21 - 23 post apg-115 treatment on cycle 1   \n",
              "12                                                                                                                                                                                                                                                                                                                                   dose-limiting toxicity (dlt) and maximum tolerated dose (mtd)|observe the activity of the combination against mantle cell lymphoma (mcl) in patients treated in this phase i study.   \n",
              "257                                                 incidence of toxicities according to the common terminology criteria for adverse events version 4|immune response as measured by the frequency of activated t-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of b-cell depletion|clinical anti-tumor response (complete response and partial response as per international workshop lymphoma response criteria [cheson 2007])|progression-free survival   \n",
              "650                                                                                                                                                                                                                                                                                                                                                                                                                 maximum tolerated dose (mtd) of 90y-hat|clinical response|number of participants with adverse events   \n",
              "810                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  safety/tolerability   \n",
              "97   determination of the maximum tolerated dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma|determination of peak concentration (cmax), trough concentration (ctrough) and/or area under the concentration versus time curve (auc) of abt-199, bendamustine and rituximab in the dose escalation cohort|number of participants with adverse events as a measure of safety and tolerability|determination of the recommended phase 2 ...   \n",
              "726                                                                                                                                                                                                                                                                                                                    maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity|pharmacokinetic parameters of dasatinib   \n",
              "640  phase 1: recommended dose of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in a pediatric population|phase 1: percentage of participants who experienced adverse events (aes) from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy|phase 1: percentage of participants who experienced serious adverse events (saes) from the first dose of protocol therapy through 30 days after administration of the last d...   \n",
              "\n",
              "     duration  target  \n",
              "741       NaN       0  \n",
              "323     936.0       1  \n",
              "243    1169.0       1  \n",
              "768     967.0       1  \n",
              "654    1701.0       1  \n",
              "316    2557.0       0  \n",
              "692    1926.0       1  \n",
              "259    1544.0       0  \n",
              "642    1857.0       0  \n",
              "625    3075.0       1  \n",
              "277    1918.0       0  \n",
              "775    3226.0       0  \n",
              "309    1279.0       0  \n",
              "30     1290.0       1  \n",
              "110    1461.0       1  \n",
              "524    1765.0       0  \n",
              "667    1725.0       1  \n",
              "736       NaN       0  \n",
              "643    1308.0       1  \n",
              "492    1885.0       0  \n",
              "361    1035.0       1  \n",
              "172    1308.0       0  \n",
              "114    1400.0       1  \n",
              "449    2471.0       1  \n",
              "479    2324.0       1  \n",
              "885    2469.0       0  \n",
              "47        NaN       1  \n",
              "130    1249.0       0  \n",
              "777    2344.0       1  \n",
              "159    1968.0       0  \n",
              "601    1095.0       0  \n",
              "663    1382.0       1  \n",
              "770    1673.0       1  \n",
              "731    1851.0       0  \n",
              "714    3530.0       1  \n",
              "23     1041.0       0  \n",
              "695       NaN       0  \n",
              "260    1461.0       1  \n",
              "374    2891.0       1  \n",
              "177     730.0       0  \n",
              "879     748.0       0  \n",
              "333    2324.0       0  \n",
              "129    1000.0       0  \n",
              "12     1249.0       0  \n",
              "257    1957.0       1  \n",
              "650    6058.0       0  \n",
              "810    1886.0       0  \n",
              "97     2976.0       1  \n",
              "726    2130.0       0  \n",
              "640    1479.0       1  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-0ddc7471-78ee-475d-9003-376dd9e01abc\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>outcome_measures</th>\n",
              "      <th>duration</th>\n",
              "      <th>target</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>741</th>\n",
              "      <td>relationship between the pharmacokinetics and measures of renal dysfunction categorized by creatinine clearance as estimated by the cockcroft and gault formula (part 1)|severity of hepatic disease as assessed by the child-pugh criteria|distribution of and association patterns between the child-pugh score and that of patient's risk of toxicity beyond each dose or cohort, assessed using the national cancer institute common terminology criteria for adverse events (nci ctcae) v3.0|mean levels of...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>323</th>\n",
              "      <td>number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events|number of subjects experiencing dose-limiting toxicities|number of subjects who develop anti-drug antibodies (ada)|time to response|duration of response|progression free survival|time to progression|event free survival|overall survival|medi4736 maximum plasma concentration (cmax)|tremelimumab maximum plasma concentration (cmax)|azd9150 maximum plasma concentration (cmax)|medi4736 ...</td>\n",
              "      <td>936.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>243</th>\n",
              "      <td>maximum tolerated dose/maximum administered dose (mtd/mad) (phase 1)|complete response rate (crr); percentage of participants experiencing positron emission tomography (pet)-negative complete response (cr) (phase 2)|overall response rate (orr); percentage of participants who achieve a pr or cr according to the lugano criteria.|orr by predictive gene signature|progression-free survival (pfs)|event-free survival (efs)|overall survival (os)|adverse events (aes)</td>\n",
              "      <td>1169.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>768</th>\n",
              "      <td>change in the absolute number of cmv-induced adaptive nk cells (cd56dimcd57+nkg2c+) between days 28 and 100 post-auto-hct in patients with lymphoid malignancies.|change in absolute number of cmv-induced adaptive nk cells|response to cmv-mva triplex vaccine in cmv seropositive vs. seronegative patients|progression free survival (pfs)|response to cmv-mva triplex vaccine in lymphoma vs. myeloma patients</td>\n",
              "      <td>967.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>654</th>\n",
              "      <td>safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ecg, and incidence and severity of adverse events|area under the plasma concentration vs. time curve (auc) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|peak plasma concentration (cmax) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously|trough plasma concentration (...</td>\n",
              "      <td>1701.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>316</th>\n",
              "      <td>maximum tolerated dose of lapatinib and everolimus (part i)|pharmacokinetics (part ii)</td>\n",
              "      <td>2557.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>692</th>\n",
              "      <td>number of participants with dose limiting toxicities (dlts)|overall response rate (orr) based on investigator assessment|overall response rate based on blinded independent review committee (birc) assessment|duration of response (dor) based on investigator assessment|duration of response (dor) based on birc|progression-free survival based on investigator assessment|progression-free survival based on birc assessment|primary pharmacokinetics (pk) parameter: auc0-last|primary pharmacokinetics (p...</td>\n",
              "      <td>1926.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>259</th>\n",
              "      <td>number of patients with adverse events|plasma concentration over time</td>\n",
              "      <td>1544.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>642</th>\n",
              "      <td>identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in cll/sll|define dose limiting toxicities of bendamustine, rituximab and lenalidomide in cll|clinical efficacy</td>\n",
              "      <td>1857.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>625</th>\n",
              "      <td>NaN</td>\n",
              "      <td>3075.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>277</th>\n",
              "      <td>the dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.|the response rate after treatment.|responsiveness of patient lymphoblasts to mtor inhibition using in-vitro and in-vivo pharmacodynamic (pd) assessments.|minimal residual disease (mrd) levels present at end of cycle 1 therapy in patients with bone marrow involvement.</td>\n",
              "      <td>1918.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>775</th>\n",
              "      <td>overall response|maximum tolerated dose (mtd) of mitoxantrone</td>\n",
              "      <td>3226.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>309</th>\n",
              "      <td>maximum tolerated dose|recommended phase ii dose|toxicity|efficacy</td>\n",
              "      <td>1279.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>safety as assessed by dose limiting toxicities (dlts)|safety as assessed by determination of the maximum tolerated dose (mtd)|safety as assessed by determination of the recommended phase 2 dose (rp2d)|safety as assessed by and adverse events, laboratory assessments and physical examinations|safety as assessed by mini-mental state examination (mmse)|overall response rate|duration of response|progression free survival|overall survival</td>\n",
              "      <td>1290.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>110</th>\n",
              "      <td>phase i part: determination of the recommended dose of rad001 in combination with rituximab.|phase ii part: complete response rate (cr+cru)|overall response rate|progression-free survival|overall survival|duration of response</td>\n",
              "      <td>1461.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>524</th>\n",
              "      <td>maximum tolerated dose (mtd) of iv amd3100 + g-csf in mobilization of peripheral blood stem cell in patients with lymphoma (phase i only)|number of participants who experienced dose limiting toxicities in phase i portion of study|kinetics of stem cell mobilization using iv amd3100 as measured by median fold change in the number of cd34+ cells after amd3100 iv administration|pharmacodynamic response to a dose of sc amd3100 as measured by mean percentage of the circulating cd34+ count with the...</td>\n",
              "      <td>1765.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>667</th>\n",
              "      <td>complete remission rate|incidence of adverse events (aes)|incidence of dose-limiting toxicities|overall best response rate|duration of response|progression-free survival</td>\n",
              "      <td>1725.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>736</th>\n",
              "      <td>rates and routes of excretion of lbh589 and its metabolites in urine and feces following administration of a single oral dose of [14c] lbh589|safety efficacy</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>643</th>\n",
              "      <td>objective response rate|assessment of the number of events and number and percentage of patients with treatment-emergent aes|time to progression|overall survival</td>\n",
              "      <td>1308.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>492</th>\n",
              "      <td>phase i-ii study of dose dense of peg-filgrastim and gm-csf combined with chop-r</td>\n",
              "      <td>1885.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>361</th>\n",
              "      <td>overall response rate (orr) of nivolumab in combination with bendamustine hydrochloride in patients with hodgkin's lymphoma|frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03|duration of response (dor)|time to progression (ttp)|progression-free survival (pfs)|overall survival (os)</td>\n",
              "      <td>1035.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>172</th>\n",
              "      <td>maximum tolerated dose of 4-hpr/lxs oral powder|safety|toxicity|level of fenretinide in normal peripheral blood mononuclear cells</td>\n",
              "      <td>1308.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>114</th>\n",
              "      <td>maximum tolerated dose (mtd) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (dlt) graded using the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 (phase i)|progression free survival (pfs) of the combination of lenalidomide, with or without idelalisib (phase ii)|overall survival (os) (phase ii)|overall response rate (partial or complete response) (phase ii)</td>\n",
              "      <td>1400.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>449</th>\n",
              "      <td>phase 1b: recommended phase 2 dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in participants with relapsed or refractory diffuse large b cell lymphoma (dlbcl)|phase 1b: number of participants with treatment-emergent adverse events (teaes), serious teaes, and discontinuations due to teaes|phase 2: overall response rate (orr)|phase 1b: orr|phase 1b: complete response (cr) rate|phase 2: cr rate|phase 2: duration of response (dor)|phase 2: progression free surviv...</td>\n",
              "      <td>2471.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>479</th>\n",
              "      <td>percentage of participants with a best overall response (or) of complete response (cr) or partial response (pr) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c)|duration of objective response (dor) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c)|percentage of participants with cr at end of treatment (eot) based on positron emission tomographic...</td>\n",
              "      <td>2324.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>885</th>\n",
              "      <td>number of participants dlt in arm 1 in dose escalation phase|number of participants dlt in arm 2 in dose escalation phase|response as per investigator assessment for patients with acute myelogenous leukemia (aml)|response as per investigator assessment for patients with acute myelogenous leukemia (aml) in expansion phase|response as per investigator assessment for patients with hodgkin's lymphoma (hd)|response as per investigator assessment for patients with myelodysplastic syndromes (mds)|m...</td>\n",
              "      <td>2469.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47</th>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>130</th>\n",
              "      <td>maximum tolerated dose (mtd) and dose limiting toxicity (dlt)|recommended phase 2 dose|pharmacokinetics (pk) in humans of intravenously administered cx-3543.|evaluate evidence of antitumor activity of cx-3543 by objective radiographic assessment.|pharmacodynamic evaluation of antitumor activity</td>\n",
              "      <td>1249.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>777</th>\n",
              "      <td>clinical response (complete or partial remission)|number of participants with dose-limiting toxicities|test the safety and tolerability of the combination of everolimus and alemtuzumab.|survival time|progression-free survival|duration of response|time to subsequent therapy</td>\n",
              "      <td>2344.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>159</th>\n",
              "      <td>maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|number of patients with adverse events</td>\n",
              "      <td>1968.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>601</th>\n",
              "      <td>tolerance and safety as measured by any ≥ grade iv granulocyte toxicity or any grade iii toxicity thought to be drug related at 1 week after each course</td>\n",
              "      <td>1095.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>663</th>\n",
              "      <td>maximum tolerated dose (mtd) and/or a recommended phase ii dose (phase i)|complete response (cr) defined as the proportion of subjects who achieve cr (phase ii)|objective response rate (orr) (phase ii)|event free survival (efs) (phase ii)|incidence of adverse events</td>\n",
              "      <td>1382.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>770</th>\n",
              "      <td>NaN</td>\n",
              "      <td>1673.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>731</th>\n",
              "      <td>maximum tolerated dose acceptable for participants|overall response rate</td>\n",
              "      <td>1851.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>714</th>\n",
              "      <td>NaN</td>\n",
              "      <td>3530.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>safety: incidence and severity of (serious) adverse events n each patient according to the nci-ctcae4.03 grading|concentration of drug in plasma</td>\n",
              "      <td>1041.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>695</th>\n",
              "      <td>maximum tolerated dose of vorinostat|safety and toxicity according to ctcae v3.0|efficacy (response rate) of vorinostat combined with rice chemotherapy|ability to proceed to peripheral blood stem cell collection following treatment</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>260</th>\n",
              "      <td>NaN</td>\n",
              "      <td>1461.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>374</th>\n",
              "      <td>mtd of lenalidomide (phase i) progression free survival (phase ii)</td>\n",
              "      <td>2891.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>177</th>\n",
              "      <td>best objective response based on recist criteria (evaluable for response analysis set for recist criteria)</td>\n",
              "      <td>730.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>879</th>\n",
              "      <td>number of infusion reaction|number of graft failure|time to neutrophil engraftment|time to platelets engraftment|number of transplant-related mortality (trm)|number of disease free survivals|number of overall survivals|number of participants at risk of gvhd|number of infectious complications|time to myeloid engraftment|time to lymphoid engraftment|change in t cell count</td>\n",
              "      <td>748.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>333</th>\n",
              "      <td>number of subjects with adverse events as a measure of safety and tolerability|disease assessments in bone marrow &amp; by computed tomography (ct)/ magnetic resonance imaging (mri)|pharmacokinetics of bms-906024 and its metabolite bms-911557: maximum observed concentration (cmax)|pharmacokinetics of bms-906024 and its metabolite bms-911557: minimum observed concentration (cmin)|pharmacokinetics of bms-906024 and its metabolite bms-911557: area under the concentration-time curve (auc)|pharmacoki...</td>\n",
              "      <td>2324.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>129</th>\n",
              "      <td>maximum tolerated dose (mtd)|response will be evaluated every 2 cycles (8 weeks), according to the revised recist guideline, version 1.1|maximum plasma concentration (cmax) of apg-115 on day 1-3 and day 21-23 post apg-115 treatment on cycle 1|area under the plasma concentration versus time curve (auc) of apg-115 on day 1 -3 and day 21 - 23 post apg-115 treatment on cycle 1</td>\n",
              "      <td>1000.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>dose-limiting toxicity (dlt) and maximum tolerated dose (mtd)|observe the activity of the combination against mantle cell lymphoma (mcl) in patients treated in this phase i study.</td>\n",
              "      <td>1249.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>257</th>\n",
              "      <td>incidence of toxicities according to the common terminology criteria for adverse events version 4|immune response as measured by the frequency of activated t-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of b-cell depletion|clinical anti-tumor response (complete response and partial response as per international workshop lymphoma response criteria [cheson 2007])|progression-free survival</td>\n",
              "      <td>1957.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>650</th>\n",
              "      <td>maximum tolerated dose (mtd) of 90y-hat|clinical response|number of participants with adverse events</td>\n",
              "      <td>6058.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>810</th>\n",
              "      <td>safety/tolerability</td>\n",
              "      <td>1886.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>determination of the maximum tolerated dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma|determination of peak concentration (cmax), trough concentration (ctrough) and/or area under the concentration versus time curve (auc) of abt-199, bendamustine and rituximab in the dose escalation cohort|number of participants with adverse events as a measure of safety and tolerability|determination of the recommended phase 2 ...</td>\n",
              "      <td>2976.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>726</th>\n",
              "      <td>maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity|pharmacokinetic parameters of dasatinib</td>\n",
              "      <td>2130.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>640</th>\n",
              "      <td>phase 1: recommended dose of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in a pediatric population|phase 1: percentage of participants who experienced adverse events (aes) from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy|phase 1: percentage of participants who experienced serious adverse events (saes) from the first dose of protocol therapy through 30 days after administration of the last d...</td>\n",
              "      <td>1479.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-0ddc7471-78ee-475d-9003-376dd9e01abc')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-0ddc7471-78ee-475d-9003-376dd9e01abc button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-0ddc7471-78ee-475d-9003-376dd9e01abc');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 53
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "dff1.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 372
        },
        "id": "l9xS5DXVHjTh",
        "outputId": "3c6cf215-4f39-47ca-df9e-abe41d4bdac0"
      },
      "execution_count": 50,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      outcome_measures  \\\n",
              "0                                                                                                                                                                                                        maximum tolerated dose|toxicity profile of et190l1 artemis™ t-cell treatment|tmax of serum cytokine levels|time to baseline for serum cytokine levels|auc of serum cytokine levels|duration of in vivo engraftment of et190l1 artemis™ t cells|rate of disease response|anti-tumor responses|b cell depletion   \n",
              "1                                                                                                                                                                                                                                                                              mtd of everolimus in combination with r-chop|adverse events profile|toxicity profile|proportion of patients who have a significant toxicity|rate of efs|overall response rate, cr rate, overall survival, pfs, and duration of response   \n",
              "2                                                                                                                                       safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes)|objective response rate based on lugano classification criteria|complete response rate based on lugano classification criteria|duration of response|progression-free survival|overall survival   \n",
              "3  percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study|percentage of participants with best overall response|maximum observed plasma concentration (cmax) under steady state of mil62|area under the plasma concentration versus time curve (auc) of mil62 under steady state|systemic clearance of mil62 under steady state|volume of distribution under steady state (vss) of mil62|terminal plasma half-life (t1/2) of mil62 under steady state|change in...   \n",
              "4                                                                                                                                                     incidence rate of dose-limiting toxicities (dlts) observed during the dlt assessment period (cycle 1) at each dose level examined|response rates|duration of response|progression-free survival (pfs)|time to next anti-lymphoma treatment (ttnlt)|overall survival (os)|incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities   \n",
              "\n",
              "   duration  target  \n",
              "0    1209.0       0  \n",
              "1    1979.0       1  \n",
              "2    1504.0       1  \n",
              "3    1204.0       1  \n",
              "4    1824.0       1  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-9deb2e5f-6cf7-4652-9205-6948e53093e4\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>outcome_measures</th>\n",
              "      <th>duration</th>\n",
              "      <th>target</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>maximum tolerated dose|toxicity profile of et190l1 artemis™ t-cell treatment|tmax of serum cytokine levels|time to baseline for serum cytokine levels|auc of serum cytokine levels|duration of in vivo engraftment of et190l1 artemis™ t cells|rate of disease response|anti-tumor responses|b cell depletion</td>\n",
              "      <td>1209.0</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>mtd of everolimus in combination with r-chop|adverse events profile|toxicity profile|proportion of patients who have a significant toxicity|rate of efs|overall response rate, cr rate, overall survival, pfs, and duration of response</td>\n",
              "      <td>1979.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes)|objective response rate based on lugano classification criteria|complete response rate based on lugano classification criteria|duration of response|progression-free survival|overall survival</td>\n",
              "      <td>1504.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study|percentage of participants with best overall response|maximum observed plasma concentration (cmax) under steady state of mil62|area under the plasma concentration versus time curve (auc) of mil62 under steady state|systemic clearance of mil62 under steady state|volume of distribution under steady state (vss) of mil62|terminal plasma half-life (t1/2) of mil62 under steady state|change in...</td>\n",
              "      <td>1204.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>incidence rate of dose-limiting toxicities (dlts) observed during the dlt assessment period (cycle 1) at each dose level examined|response rates|duration of response|progression-free survival (pfs)|time to next anti-lymphoma treatment (ttnlt)|overall survival (os)|incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities</td>\n",
              "      <td>1824.0</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-9deb2e5f-6cf7-4652-9205-6948e53093e4')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-9deb2e5f-6cf7-4652-9205-6948e53093e4 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-9deb2e5f-6cf7-4652-9205-6948e53093e4');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 50
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"scat\" , y=\"duration\",palette=\"Set2\", data=dff1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 371
        },
        "id": "SeK7qw-rk-QN",
        "outputId": "970b2d94-0ebe-424b-95b1-31553a60981d"
      },
      "execution_count": 49,
      "outputs": [
        {
          "output_type": "error",
          "ename": "ValueError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-49-c5a26813e393>\u001b[0m in \u001b[0;36m<cell line: 2>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0mfig\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mplt\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfigure\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 2\u001b[0;31m \u001b[0max\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0msns\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbarplot\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"scat\"\u001b[0m \u001b[0;34m,\u001b[0m \u001b[0my\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"duration\"\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mpalette\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"Set2\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdff1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      3\u001b[0m \u001b[0mplt\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mshow\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/seaborn/categorical.py\u001b[0m in \u001b[0;36mbarplot\u001b[0;34m(data, x, y, hue, order, hue_order, estimator, errorbar, n_boot, units, seed, orient, color, palette, saturation, width, errcolor, errwidth, capsize, dodge, ci, ax, **kwargs)\u001b[0m\n\u001b[1;32m   2753\u001b[0m         \u001b[0mestimator\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m\"size\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2754\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 2755\u001b[0;31m     plotter = _BarPlotter(x, y, hue, data, order, hue_order,\n\u001b[0m\u001b[1;32m   2756\u001b[0m                           \u001b[0mestimator\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0merrorbar\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mn_boot\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0munits\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mseed\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2757\u001b[0m                           \u001b[0morient\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcolor\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mpalette\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msaturation\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/seaborn/categorical.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, x, y, hue, data, order, hue_order, estimator, errorbar, n_boot, units, seed, orient, color, palette, saturation, width, errcolor, errwidth, capsize, dodge)\u001b[0m\n\u001b[1;32m   1528\u001b[0m                  errcolor, errwidth, capsize, dodge):\n\u001b[1;32m   1529\u001b[0m         \u001b[0;34m\"\"\"Initialize the plotter.\"\"\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1530\u001b[0;31m         self.establish_variables(x, y, hue, data, orient,\n\u001b[0m\u001b[1;32m   1531\u001b[0m                                  order, hue_order, units)\n\u001b[1;32m   1532\u001b[0m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mestablish_colors\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcolor\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mpalette\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msaturation\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/seaborn/categorical.py\u001b[0m in \u001b[0;36mestablish_variables\u001b[0;34m(self, x, y, hue, data, orient, order, hue_order, units)\u001b[0m\n\u001b[1;32m    539\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvar\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    540\u001b[0m                     \u001b[0merr\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34mf\"Could not interpret input '{var}'\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 541\u001b[0;31m                     \u001b[0;32mraise\u001b[0m \u001b[0mValueError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0merr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    542\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    543\u001b[0m             \u001b[0;31m# Figure out the plotting orientation\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mValueError\u001b[0m: Could not interpret input 'scat'"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 0 Axes>"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# EFF vs non safety 2\n",
        "pattern = re.compile(r\"\\b(dlt|ae|dose limit toxicity|toxicity|pk|pd)\\b\", re.IGNORECASE)\n",
        "dff1[\"dltcat\"]=np.where(dff1[\"outcome_measures\"].str.contains(pattern),\"DLT\" ,\"EFFSolo\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XMvtInhjlPlY",
        "outputId": "9abcf19b-3cac-49c7-d932-1d16115ca4a2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-47-b1a629a02016>:3: UserWarning: This pattern is interpreted as a regular expression, and has match groups. To actually get the groups, use str.extract.\n",
            "  dff1[\"dltcat\"]=np.where(dff1[\"outcome_measures\"].str.contains(pattern),\"DLT\" ,\"EFFSolo\")\n",
            "<ipython-input-47-b1a629a02016>:3: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  dff1[\"dltcat\"]=np.where(dff1[\"outcome_measures\"].str.contains(pattern),\"DLT\" ,\"EFFSolo\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fig=plt.figure()\n",
        "ax=sns.barplot(x=\"dltcat\" , y=\"duration\",palette=\"Set2\", data=dff1)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 449
        },
        "id": "Lh433mOJluln",
        "outputId": "29d38263-4093-4b15-8ec5-af4ac7eb537a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "train_df.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 354
        },
        "id": "T_f_E2gtHtbn",
        "outputId": "a540955d-6c19-4fe0-be45-19c29788fae9"
      },
      "execution_count": 52,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      outcome_measures  \\\n",
              "0                                                                                                                                                                                                        maximum tolerated dose|toxicity profile of et190l1 artemis™ t-cell treatment|tmax of serum cytokine levels|time to baseline for serum cytokine levels|auc of serum cytokine levels|duration of in vivo engraftment of et190l1 artemis™ t cells|rate of disease response|anti-tumor responses|b cell depletion   \n",
              "1                                                                                                                                                                                                                                                                              mtd of everolimus in combination with r-chop|adverse events profile|toxicity profile|proportion of patients who have a significant toxicity|rate of efs|overall response rate, cr rate, overall survival, pfs, and duration of response   \n",
              "2                                                                                                                                       safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes)|objective response rate based on lugano classification criteria|complete response rate based on lugano classification criteria|duration of response|progression-free survival|overall survival   \n",
              "3  percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study|percentage of participants with best overall response|maximum observed plasma concentration (cmax) under steady state of mil62|area under the plasma concentration versus time curve (auc) of mil62 under steady state|systemic clearance of mil62 under steady state|volume of distribution under steady state (vss) of mil62|terminal plasma half-life (t1/2) of mil62 under steady state|change in...   \n",
              "4                                                                                                                                                     incidence rate of dose-limiting toxicities (dlts) observed during the dlt assessment period (cycle 1) at each dose level examined|response rates|duration of response|progression-free survival (pfs)|time to next anti-lymphoma treatment (ttnlt)|overall survival (os)|incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities   \n",
              "\n",
              "   duration  \n",
              "0    1209.0  \n",
              "1    1979.0  \n",
              "2    1504.0  \n",
              "3    1204.0  \n",
              "4    1824.0  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-26ccdf2d-1670-4946-9286-ca614f5e1c17\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>outcome_measures</th>\n",
              "      <th>duration</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>maximum tolerated dose|toxicity profile of et190l1 artemis™ t-cell treatment|tmax of serum cytokine levels|time to baseline for serum cytokine levels|auc of serum cytokine levels|duration of in vivo engraftment of et190l1 artemis™ t cells|rate of disease response|anti-tumor responses|b cell depletion</td>\n",
              "      <td>1209.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>mtd of everolimus in combination with r-chop|adverse events profile|toxicity profile|proportion of patients who have a significant toxicity|rate of efs|overall response rate, cr rate, overall survival, pfs, and duration of response</td>\n",
              "      <td>1979.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes)|objective response rate based on lugano classification criteria|complete response rate based on lugano classification criteria|duration of response|progression-free survival|overall survival</td>\n",
              "      <td>1504.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study|percentage of participants with best overall response|maximum observed plasma concentration (cmax) under steady state of mil62|area under the plasma concentration versus time curve (auc) of mil62 under steady state|systemic clearance of mil62 under steady state|volume of distribution under steady state (vss) of mil62|terminal plasma half-life (t1/2) of mil62 under steady state|change in...</td>\n",
              "      <td>1204.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>incidence rate of dose-limiting toxicities (dlts) observed during the dlt assessment period (cycle 1) at each dose level examined|response rates|duration of response|progression-free survival (pfs)|time to next anti-lymphoma treatment (ttnlt)|overall survival (os)|incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities</td>\n",
              "      <td>1824.0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-26ccdf2d-1670-4946-9286-ca614f5e1c17')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-26ccdf2d-1670-4946-9286-ca614f5e1c17 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-26ccdf2d-1670-4946-9286-ca614f5e1c17');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 52
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def chat(prompt):\n",
        "\n",
        "   openai.api_key = \"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\"\n",
        "\n",
        "   try:\n",
        "\n",
        "      response = openai.ChatCompletion.create(\n",
        "      model = \"gpt-3.5-turbo\",\n",
        "      messages = [{\"role\": 'system', \"content\": f'{prompt}'}]\n",
        "      )\n",
        "\n",
        "      answer = response[\"choices\"][0][\"message\"][\"content\"]\n",
        "      usage = response[\"usage\"][\"total_tokens\"]\n",
        "\n",
        "      return answer, usage\n",
        "\n",
        "\n",
        "   except openai.error.RateLimitError as e:\n",
        "\n",
        "      retry_time = e.retry_after if hasattr(e, 'retry_after') else 30\n",
        "      print(f\"Rate limit exceeded. Retrying in {retry_time} seconds...\")\n",
        "      time.sleep(retry_time)\n",
        "      return chat(prompt)\n",
        "\n",
        "   except openai.error.ServiceUnavailableError as e:\n",
        "      retry_time = 10  # Adjust the retry time as needed\n",
        "      print(f\"Service is unavailable. Retrying in {retry_time} seconds...\")\n",
        "      time.sleep(retry_time)\n",
        "      return chat(prompt)\n",
        "\n",
        "   except openai.error.APIError as e:\n",
        "      retry_time = e.retry_after if hasattr(e, 'retry_after') else 30\n",
        "      print(f\"API error occurred. Retrying in {retry_time} seconds...\")\n",
        "      time.sleep(retry_time)\n",
        "      return chat(prompt)\n",
        "\n",
        "   except OSError as e:\n",
        "        retry_time = 5  # Adjust the retry time as needed\n",
        "        print(f\"Connection error occurred: {e}. Retrying in {retry_time} seconds...\")\n",
        "        time.sleep(retry_time)\n",
        "        return chat(prompt)"
      ],
      "metadata": {
        "id": "pCC3BugNLd_J"
      },
      "execution_count": 59,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import time"
      ],
      "metadata": {
        "id": "oUdrV09-gfP0"
      },
      "execution_count": 60,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "messages = [\n",
        "    # system: define chatGPT's role and the tone of chatGPT\n",
        "    {\"role\": \"system\",\n",
        "     \"content\": 'You can only use \"1\" or \"0\" as your answer. Please use your best judgement. If you are not sure about the answer, then just guess one.'},\n",
        "    # simulate conversations like https://chat.openai.com/chat\n",
        "    # assistant is chatgpt, user is us\n",
        "    {\"role\": \"user\", \"content\": \"\"\"Please read the following outcome measures include overall survive or OS. Please answer \"1\" if it is, and \"0\" if it's not.\n",
        "     The outcome measure is \"overall survival median|3-year overall survival\".\"\"\"},\n",
        "    {\"role\": \"assistant\", \"content\": \"1\"},\n",
        "    {\"role\": \"user\", \"content\": \"overall survival (os)...\"},\n",
        "    {\"role\": \"assistant\", \"content\": \"1\"}\n",
        "]\n",
        "\n",
        "chat_raw_results, correct = [], 1\n",
        "for row in train_df.iterrows():\n",
        "    outcome_measures, target = row[1]['outcome_measures'], str(row[1]['target'])\n",
        "\n",
        "    # # with feedback\n",
        "    # if correct:\n",
        "    #     content = f'''Your answer is correct. How about this tweet \"{tweet_text}\"'''\n",
        "    # else:\n",
        "    #     content = f'''Your answer is wrong. How about this tweet \"{tweet_text}\"'''\n",
        "    # messages.append({\"role\": \"user\", \"content\":content})\n",
        "\n",
        "    # without feedback\n",
        "    last_message=messages[1]\n",
        "    if last_message[\"role\"]==\"user\":\n",
        "      messages=messages[:-1]\n",
        "    messages.append({\"role\": \"user\", \"content\":outcome_measures})\n",
        "    completion = openai.ChatCompletion.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=messages)\n",
        "    chat_response = completion.choices[0].message.content\n",
        "    #chat_raw_results.append(chat_response)\n",
        "    correct = 1 if chat_response == str(target) else 0\n",
        "    # messages.append({\"role\": \"assistant\", \"content\":chat_response})\n",
        "    time.sleep(np.random.randint(1))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 425
        },
        "id": "kvugtI5igjGH",
        "outputId": "1a90375a-55a6-445e-cb95-2836cc419c41"
      },
      "execution_count": 62,
      "outputs": [
        {
          "output_type": "error",
          "ename": "InvalidRequestError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mInvalidRequestError\u001b[0m                       Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-62-1e4e1f708d59>\u001b[0m in \u001b[0;36m<cell line: 15>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     28\u001b[0m       \u001b[0mmessages\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmessages\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m-\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     29\u001b[0m     \u001b[0mmessages\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m{\u001b[0m\u001b[0;34m\"role\"\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;34m\"user\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"content\"\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0moutcome_measures\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 30\u001b[0;31m     completion = openai.ChatCompletion.create(\n\u001b[0m\u001b[1;32m     31\u001b[0m         \u001b[0mmodel\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"gpt-3.5-turbo\"\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     32\u001b[0m         messages=messages)\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/openai/api_resources/chat_completion.py\u001b[0m in \u001b[0;36mcreate\u001b[0;34m(cls, *args, **kwargs)\u001b[0m\n\u001b[1;32m     23\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     24\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 25\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcreate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     26\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mTryAgain\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     27\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0mtimeout\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mtime\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0mstart\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/openai/api_resources/abstract/engine_api_resource.py\u001b[0m in \u001b[0;36mcreate\u001b[0;34m(cls, api_key, api_base, api_type, request_id, api_version, organization, **params)\u001b[0m\n\u001b[1;32m    151\u001b[0m         )\n\u001b[1;32m    152\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 153\u001b[0;31m         response, _, api_key = requestor.request(\n\u001b[0m\u001b[1;32m    154\u001b[0m             \u001b[0;34m\"post\"\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    155\u001b[0m             \u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/openai/api_requestor.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(self, method, url, params, headers, files, stream, request_id, request_timeout)\u001b[0m\n\u001b[1;32m    296\u001b[0m             \u001b[0mrequest_timeout\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mrequest_timeout\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    297\u001b[0m         )\n\u001b[0;32m--> 298\u001b[0;31m         \u001b[0mresp\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mgot_stream\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_interpret_response\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mresult\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstream\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    299\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mgot_stream\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapi_key\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    300\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/openai/api_requestor.py\u001b[0m in \u001b[0;36m_interpret_response\u001b[0;34m(self, result, stream)\u001b[0m\n\u001b[1;32m    698\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    699\u001b[0m             return (\n\u001b[0;32m--> 700\u001b[0;31m                 self._interpret_response_line(\n\u001b[0m\u001b[1;32m    701\u001b[0m                     \u001b[0mresult\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcontent\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdecode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"utf-8\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    702\u001b[0m                     \u001b[0mresult\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstatus_code\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/openai/api_requestor.py\u001b[0m in \u001b[0;36m_interpret_response_line\u001b[0;34m(self, rbody, rcode, rheaders, stream)\u001b[0m\n\u001b[1;32m    761\u001b[0m         \u001b[0mstream_error\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mstream\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;34m\"error\"\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    762\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mstream_error\u001b[0m \u001b[0;32mor\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;36m200\u001b[0m \u001b[0;34m<=\u001b[0m \u001b[0mrcode\u001b[0m \u001b[0;34m<\u001b[0m \u001b[0;36m300\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 763\u001b[0;31m             raise self.handle_error_response(\n\u001b[0m\u001b[1;32m    764\u001b[0m                 \u001b[0mrbody\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mrcode\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mrheaders\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstream_error\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mstream_error\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    765\u001b[0m             )\n",
            "\u001b[0;31mInvalidRequestError\u001b[0m: We could not parse the JSON body of your request. (HINT: This likely means you aren't using your HTTP library correctly. The OpenAI API expects a JSON payload, but what was sent was not valid JSON. If you have trouble figuring out how to fix this, please contact us through our help center at help.openai.com.)"
          ]
        }
      ]
    }
  ]
}